Related Experiment Video
Updated: Apr 24, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study
K Lerang1, I-M Gilboe2, D Steinar Thelle3
1Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway klerang@ous-hf.no.
Insights
Systemic lupus erythematosus (SLE) patients face significantly reduced survival rates and a higher risk of premature death compared to the general population. Years of Potential Life Lost (YPLL) offers valuable insights into SLE prognosis.
Area of Science:
- Rheumatology
- Epidemiology
- Public Health
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant morbidity and mortality.
- Assessing long-term outcomes and mortality patterns in SLE patients is crucial for understanding disease impact.
Purpose of the Study:
- To evaluate survival, mortality rates, and causes of death in a cohort of SLE patients in Oslo.
- To compare SLE patient mortality with the general population using Standardized Mortality Ratio (SMR) and Years of Potential Life Lost before 60 (YPLL60).
Main Methods:
- Identification of 325 SLE patients meeting American College of Rheumatology (ACR) criteria in Oslo (1999-2009).
- Analysis of survival (inception cohort, n=127), SMR, YPLL60, and causes of death.
- Comparison with a matched general population control group.
Main Results:
- Five- and 10-year survival rates were 95% and 90%, significantly lower than controls.
- Overall SMR was 3.0, with highest rates in females aged 16-39.
- SLE patients exhibited a 10-fold higher YPLL60 compared to controls, highlighting premature mortality.
Conclusions:
- SLE patients experience reduced survival and increased premature mortality.
- YPLL60 provides a valuable metric for assessing SLE prognosis, emphasizing active disease impact.
- Mortality analysis in SLE should incorporate YPLL to supplement traditional measures.
Abstract:
Multiple sources were used to identify 325 systemic lupus erythematosus (SLE) patients within the city of Oslo during 1999-2009 who met ≥ 4 of the American College of Rheumatology (ACR) criteria. The survival, standard mortality rate (SMR), years of potential life loss before 60 years of age (YPLL60) and causes of death of these patients were examined and compared to a matched control population. Only inception cases (127) were studied in the calculation of survival. The analysis includes underlying, immediate and contributing causes of death. The five- and 10-year survival was 95% and 90%, respectively, which was significantly reduced when compared to the general population. A total of 50 SLE patients died during the study period. Overall SMR was 3.0 (95% confidence interval (CI) 2.2-3.8) with the highest SMR found for female patients aged 16-39 years old. SLE patients had a 10 times higher rate of YPLL60 compared to the control group. YPLL emphasizes active disease and reduces the importance of cancer as a cause of death in SLE. This study demonstrates that YPLL gives additional and useful information for the prognosis of SLE, supplementing traditional methods of measuring mortality.
Related Concept Videos
Life Tables
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Multiple Sclerosis l: Introduction
Applications of Life Tables

